318 related articles for article (PubMed ID: 26208817)
1. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
Öztürk H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
[TBL] [Abstract][Full Text] [Related]
2. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
3. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
4. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
5. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
6. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
7. FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.
Mertens LS; Fioole-Bruining A; van Rhijn BW; Kerst JM; Bergman AM; Vogel WV; Vegt E; Horenblas S
J Urol; 2013 May; 189(5):1687-91. PubMed ID: 23142689
[TBL] [Abstract][Full Text] [Related]
8. Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging.
Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P; Buvat I
J Nucl Med; 2011 Mar; 52(3):354-61. PubMed ID: 21345787
[TBL] [Abstract][Full Text] [Related]
9. Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT.
Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
J Radiat Res; 2015 May; 56(3):553-60. PubMed ID: 25829531
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
van de Putte EEF; Vegt E; Mertens LS; Bruining A; Hendricksen K; van der Heijden MS; Horenblas S; van Rhijn BWG
Int Urol Nephrol; 2017 Sep; 49(9):1585-1591. PubMed ID: 28674853
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans.
Monteil J; Mahmoudi N; Leobon S; Roudaut PY; El Badaoui A; Verbeke S; Venat-Bouvet L; Martin J; Le Brun-Ly V; Lavau-Denes S; Maubon A; Bouillet P; Pouquet M; Vandroux JC; Tubiana-Mathieu N
Anticancer Res; 2009 Jul; 29(7):2563-8. PubMed ID: 19596929
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
14. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
15. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
[TBL] [Abstract][Full Text] [Related]
16. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
17. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
20. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F
Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
